



Modecate Abbreviated Prescribing Information. Indications: Treatment of psychotic disorders. **Dosage – Modecate injection 25mg/ml.** Most patients are successfully maintained within the dosage range 12.5mg (0.5ml) every five weeks to 100mg (4ml) every two weeks. For full dosage information see Data Sheet. **Modecate concentrate injection 100mg/ml.** Adult patients found to require larger volumes of Modecate 25mg/ml may be transferred directly to the equivalent dose of Modecate concentrate on the basis that 1ml Modecate concentrate is equivalent to 4ml Modecate. **Contra-indications.** Patients with marked cerebral atherosclerosis, phaeochromocytoma, renal or liver failure, or severe cardiac insufficiency. **Precautions.** Care should be taken in patients, particularly the elderly, who exhibit marked extrapyramidal reactions to oral phenothiazines. **Side effects.** Mainly extrapyramidal reactions. Drowsiness, lethargy, dryness of the mouth and mild hypotension may occur. **Product Licence No's and Prices.** **Modecate injection 25mg/ml.** PL 0034/5046. 10 x 1ml ampoule £25.20 **Modecate concentrate injection 100mg/ml.** PL 0034/0189. 10 x 0.5ml ampoule £49.99 5 x 1.0ml ampoule £48.86. Modecate is a Trade Mark of E. R. Squibb & Sons Ltd. Further information available from: Technical Services Department, E. R. Squibb & Sons Ltd., 141-149 Staines Road, Hounslow, Middlesex TW3 3JA. Tel: 01-572 7422.



TRIED AND TRUSTED

19 years ago, E. R. Squibb & Sons helped lead a revolution in the community based treatment of schizophrenia when they introduced the depot neuroleptic concept. Since then worldwide clinical experience has confirmed the efficacy and safety of Modecate in over 800,000 patients. Modecate is now regarded by many psychiatrists as the standard depot neuroleptic.




Modecate is available in two strengths, allowing a wide dosage range with convenient injection volumes. Most patients can be controlled with an injection at intervals of 3 weeks or more.¹ Modecate is less expensive than other depot neuroleptics when comparing equipotent doses.

¹) Johnson DAW Br J Psychiat 1975; 126: 457-461.

E. R. Squibb & Sons Ltd., 141-149 Staines Road, Hounslow, Middlesex TW3 3JA. Tel: 01-572 7422.





For over ten years, psychiatrists abroad have had access to a unique antipsychotic agent.

Now, with the introduction of Dolmatil in Ireland, a major new dimension is added to the area of schizophrenic therapy, for patients presenting with either positive or negative symptoms.

One of the major drawbacks with conventional neuroleptics has been their inability to treat patients presenting with typical negative symptoms of chronic schizophrenia.

In these patients, Dolmatil will have an alerting and antidepressant effect, significantly increasing drive and motivation.^{1,2,3} And, in over a decade of use, there have been virtually no reports of tardive dyskinesia when Dolmatil has been used alone.

Dolmatil offers the psychiatrist the first real alternative to conventional neuroleptics and an opportunity to change the perspective in schizophrenia.

Dolmatil^{sulpride}[™]

A CHANGING PERSPECTIVE IN SCHIZOPHRENIA

¹Elizur, A, Davidson, S. *Curr Ther Res* 1975; 18: 578-584. ²Niskanen, P et al. *Curr Ther Res*, 17: 281-284. ³Soni, S D. Schizophrenia. *New Pharmacological and Clinical Developments*, 1985; 147: 283-288.

FULL PRESCRIBING INFORMATION AVAILABLE ON REQUEST FROM: TECHNICAL SERVICES DEPARTMENT, SQUIBB (IRELAND) LIMITED, SWORDS, CO. DUBLIN. TEL: (01) 401471. PA. No 387/2/1

